Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ARDT vs DBVT vs HCA vs ALKS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
Medical - Distribution
ARDT vs DBVT vs HCA vs ALKS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology | Medical - Distribution |
| Market Cap | $1.41B | $1712.35T | $95.95B | $5.90B | $92.15B |
| Revenue (TTM) | $6.43B | $0.00 | $75.60B | $1.56B | $403.43B |
| Net Income (TTM) | $134M | $-168M | $6.78B | $153M | $4.76B |
| Gross Margin | 60.5% | — | 41.5% | 65.4% | 3.6% |
| Operating Margin | 8.9% | — | 15.8% | 12.3% | 1.5% |
| Forward P/E | 8.7x | — | 14.2x | 24.8x | 19.3x |
| Total Debt | $2.26B | $22M | $50.20B | $70M | $7.39B |
| Cash & Equiv. | $710M | $194M | $1.04B | $1.12B | $5.69B |
ARDT vs DBVT vs HCA vs ALKS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Ardent Health Partn… (ARDT) | 100 | 55.3 | -44.7% |
| DBV Technologies S.… (DBVT) | 100 | 330.4 | +230.4% |
| HCA Healthcare, Inc. (HCA) | 100 | 118.2 | +18.2% |
| Alkermes plc (ALKS) | 100 | 129.6 | +29.6% |
| McKesson Corporation (MCK) | 100 | 121.9 | +21.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARDT vs DBVT vs HCA vs ALKS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARDT ranks third and is worth considering specifically for value.
- Lower P/E (8.7x vs 24.8x)
DBVT is the clearest fit if your priority is momentum.
- +110.4% vs ARDT's -30.5%
HCA has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- 450.5% 10Y total return vs MCK's 348.1%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 0.7% yield, 5-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs DBVT's 0.3%
MCK is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- PEG 0.49 vs HCA's 0.67
- 16.2% revenue growth vs DBVT's -100.0%
- Beta 0.04 vs ARDT's 1.40
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (8.7x vs 24.8x) | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.04 vs ARDT's 1.40 | |
| Dividends | 0.7% yield, 5-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs ARDT's -30.5% | |
| Efficiency (ROA) | 11.3% ROA vs DBVT's -89.0% |
ARDT vs DBVT vs HCA vs ALKS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ARDT vs DBVT vs HCA vs ALKS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 2 of 6 categories
ALKS leads 1 • ARDT leads 1 • DBVT leads 0 • HCA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to MCK's 1.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6.4B | $0 | $75.6B | $1.6B | $403.4B |
| EBITDAEarnings before interest/tax | $733M | -$112M | $15.5B | $212M | $6.8B |
| Net IncomeAfter-tax profit | $134M | -$168M | $6.8B | $153M | $4.8B |
| Free Cash FlowCash after capex | $214M | -$151M | $7.7B | $392M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +60.5% | — | +41.5% | +65.4% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +8.9% | — | +15.8% | +12.3% | +1.5% |
| Net MarginNet income ÷ Revenue | +2.1% | — | +9.0% | +9.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | +3.3% | — | +10.2% | +25.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.0% | — | +6.7% | +28.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +91.5% | +44.6% | -4.1% | +37.0% |
Valuation Metrics
ARDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 10.3x trailing earnings, ARDT trades at a 65% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), HCA offers better value at 0.72x vs MCK's 0.75x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.4B | $1712.35T | $95.9B | $5.9B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $1712.35T | $145.1B | $4.9B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 10.29x | -0.76x | 15.12x | 24.76x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.65x | — | 14.19x | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.72x | — | 0.75x |
| EV / EBITDAEnterprise value multiple | 6.17x | — | 9.37x | 17.25x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.22x | — | 1.27x | 4.00x | 0.26x |
| Price / BookPrice ÷ Book value/share | 0.83x | 0.66x | — | 3.28x | — |
| Price / FCFMarket cap ÷ FCF | 5.47x | — | 12.47x | 12.28x | 17.63x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDT's 1.34x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.0% | -130.2% | — | +8.8% | +3.0% |
| ROA (TTM)Return on assets | +2.6% | -89.0% | +11.3% | +5.4% | +5.7% |
| ROICReturn on invested capital | +7.5% | — | +19.9% | +18.9% | +5.4% |
| ROCEReturn on capital employed | +7.9% | -145.7% | +27.0% | +14.2% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 7 | 6 |
| Debt / EquityFinancial leverage | 1.34x | 0.13x | — | 0.04x | — |
| Net DebtTotal debt minus cash | $1.6B | -$172M | $49.2B | -$1.0B | $1.7B |
| Cash & Equiv.Liquid assets | $710M | $194M | $1.0B | $1.1B | $5.7B |
| Total DebtShort + long-term debt | $2.3B | $22M | $50.2B | $70M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 6.36x | -189.82x | 5.37x | 32.30x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ARDT's -30.5%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs ARDT's -15.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.4% | +4.9% | -8.6% | +25.3% | -8.5% |
| 1-Year ReturnPast 12 months | -30.5% | +110.4% | +19.7% | +16.5% | +4.6% |
| 3-Year ReturnCumulative with dividends | -38.5% | +19.7% | +57.4% | +14.5% | +106.4% |
| 5-Year ReturnCumulative with dividends | -38.5% | -69.1% | +109.7% | +60.9% | +286.9% |
| 10-Year ReturnCumulative with dividends | -38.5% | -87.0% | +450.5% | -11.0% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -15.0% | +6.2% | +16.3% | +4.6% | +27.3% |
Risk & Volatility
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than ARDT's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs ARDT's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 1.26x | 0.29x | 1.06x | 0.04x |
| 52-Week HighHighest price in past year | $15.48 | $26.18 | $556.52 | $36.60 | $999.00 |
| 52-Week LowLowest price in past year | $8.07 | $7.53 | $330.00 | $25.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +76.3% | +77.1% | +96.7% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 48.1 | 30.8 | 60.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 382K | 252K | 1000K | 2.3M | 757K |
Analyst Outlook
Evenly matched — HCA and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ARDT as "Buy", DBVT as "Buy", HCA as "Buy", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.9% for HCA (target: $527). For income investors, HCA offers the higher dividend yield at 0.69% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $13.33 | $46.33 | $527.45 | $44.00 | $1006.50 |
| # AnalystsCovering analysts | 12 | 15 | 46 | 28 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 5 | 0 | 17 |
| Dividend / ShareAnnual DPS | — | — | $2.94 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +10.5% | +0.5% | +3.4% |
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
ARDT vs DBVT vs HCA vs ALKS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ARDT or DBVT or HCA or ALKS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Ardent Health Partners, LLC (ARDT) offers the better valuation at 10. 3x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Ardent Health Partners, LLC (ARDT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARDT or DBVT or HCA or ALKS or MCK?
On trailing P/E, Ardent Health Partners, LLC (ARDT) is the cheapest at 10.
3x versus McKesson Corporation at 29. 2x. On forward P/E, Ardent Health Partners, LLC is actually cheaper at 8. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ARDT or DBVT or HCA or ALKS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HCA returned +450. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARDT or DBVT or HCA or ALKS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Ardent Health Partners, LLC's 1. 40β — meaning ARDT is approximately 3147% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 134% for Ardent Health Partners, LLC — giving it more financial flexibility in a downturn.
05Which is growing faster — ARDT or DBVT or HCA or ALKS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: HCA Healthcare, Inc. grew EPS 29. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARDT or DBVT or HCA or ALKS or MCK?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ARDT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARDT or DBVT or HCA or ALKS or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Ardent Health Partners, LLC (ARDT) trades at 8. 7x forward P/E versus 19. 3x for McKesson Corporation — 10. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — ARDT or DBVT or HCA or ALKS or MCK?
In this comparison, HCA (0.
7% yield), MCK (0. 4% yield) pay a dividend. ARDT, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is ARDT or DBVT or HCA or ALKS or MCK better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, ARDT: -38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARDT and DBVT and HCA and ALKS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ARDT is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; HCA is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. HCA pays a dividend while ARDT, DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.